This study is for adults with Relapsed/Refractory Multiple Myeloma, a type of blood cancer that returns after treatment. The treatment, called GC012F (AZD0120), is a special kind of therapy known as CAR T-cell therapy. It targets two proteins, CD19 and BCMA, on the cancer cells to help fight the disease.
The study has two phases. In Phase 1b, it checks how safe the treatment is and how it behaves in the body. Phase 2 looks at how well the treatment works and how it affects patients' health and quality of life.
- Participation: You must be 18 or older, with at least three prior treatments for multiple myeloma.
- Study Length: The study involves multiple visits to the study doctor to monitor health and response to treatment.
- Risks: Potential side effects include reactions from the therapy, and your heart health will be checked.
Discuss with your doctor if you meet the criteria and are interested in joining. The study aims to improve treatment for those with few other options.
How understandable was the trial content above?
Hard to understand
Easy to understand